论文部分内容阅读
本文讨论了药品名称审定的有关问题,并扼要介绍了世界卫生组织拟定的INN命名原则。关于药品的商品名称,目前争论较多。笔者认为,如从鼓励竞争、选优淘劣的角度考虑,药品的商品名称应该允许存在,但必须有相应的命名规则与严格的审定和管理办法。对于有机药物的化学名称,本文建议最好能全部改用系统名称,尽可能与CA的命名一致起来。
This article discusses issues related to the validation of names of drugs and outlines the principles of naming INN developed by the World Health Organization. The name of the drug product, the current debate more. The author believes that from the perspective of encouraging competition, selection and optimization, the product name of the drug should be allowed to exist, but there must be corresponding naming rules and strict validation and management practices. For the chemical name of organic drugs, this article suggests that the best can all use the system name, as far as possible consistent with the CA’s name.